2026 Catalysts: Psychiatry, epilepsy and neurodegeneration

Neuroscience remains one of the industry’s riskiest arenas, but 2026 brings a dense catalyst calendar, with clusters of late-stage readouts in psychedelics and epilepsy, and proof-of-concept data across a range of genetically anchored neurodegeneration programs.

This analysis, anchored by a 25-slide deck, lays out key milestones to watch in 2026, from regulatory decisions that could bring new products to patients, to Phase III readouts that could set up regulatory submissions, to POC data that could support new targets, delivery strategies or biomarker-led development strategies. The selection is not comprehensive...